Research
Jan 22, 2023
HPTN 076 was a two-year study that recruited sexually active women age 18 to 45 and evaluated the safety and acceptability of a new injectable HIV prevention medication, Rilpivirine, for use in healthy, HIV-uninfected women. Report Links: Seneviratne HK et al. 2020....
Jan 21, 2023
HPTN 091 is a study assessing the feasibility, acceptability, preliminary impact of a multi-component strategy that provides HIV prevention services, gender-affirming hormone therapy, and Peer Health Navigation to improve pre-exposure prophylaxis (PrEP) uptake and...
Jan 20, 2023
A vanguard study of health service delivery in a mobile health delivery unit to link persons who inject opiates to integrated care and prevention for addiction, HIV, hepatitis, STIs and primary care Web Links: https://clinicaltrials.gov/ct2/show/NCT04804072...
Jan 19, 2023
HPTN 083 recruited HIV-uninfected men who have sex with men and transgender women at risk for acquiring HIV infection to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for PrEP and demonstrated the superiority of cabotegravir for HIV...
Jan 18, 2023
Primary objective 1: To identify serologic reactivities that differentiate SARS-CoV-2 infection from vaccination. Primary objective 2: To develop and formally qualify a suite of immunologic assays and reference reagents that permit detailed interrogations of the...
